This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Anne L. Coleman, MD; D. L. Chris Diehl, MD; Henry D. Jampel, MD; Paul S. Bachorik, PhD; Harry A. Quigley, MD

Arch Ophthalmol. 1990;108(9):1260-1263.

Abstract
• β-Adrenergic antagonists taken orally adversely alter plasma lipid profiles. This study was designed to determine whether 0.5% topical timolol maleate has a similar effect. Forty volunteers who were not using medications known to alter plasma lipid levels were recruited for an unmasked study in which each subject served as his or her own control. Twelve subjects did not complete the study because of ocular and systemic side effects or extraneous factors. Twenty-eight subjects used topical timolol for an average of 76 days, with two 12-hour fasting plasma specimens obtained at the beginning and end of the period. Mean total cholesterol and low-density lipoprotein cholesterol levels did not change significantly with treatment. Triglyceride values increased 12%; high-density lipoprotein cholesterol levels decreased 9%; and the total cholesterol-high-density lipoprotein cholesterol ratio increased 8%. Higher baseline high-density lipoprotein cholesterol levels were associated with larger reductions in high-density lipoprotein cholesterol levels. Changes in high-density lipoprotein cholesterol levels of this magnitude have been estimated to increase the risk of coronary artery disease by 21%.

Author Affiliations
From the Glaucoma Service, Wilmer Ophthalmological Institute (Drs Coleman, Diehl, Jampel, and Quigley), and the Johns Hopkins Lipid Research Atherosclerosis Unit, Johns Hopkins University School of Medicine (Dr Bachorik), Baltimore, Md. Dr Coleman is now with the Department of Ophthalmology, UCLA School of Medicine.

Footnotes
Accepted for publication May 8, 1990.

Reprint requests to JSEI, 2-118, 100 Stein Plaza, UCLA, Los Angeles, CA 90024-7004 (Dr Coleman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intraocular Pressure Response to Topical {beta}-Blockers Associated With an ADRB2 Single-Nucleotide Polymorphism
McCarty et al.
Arch Ophthalmol 2008;126:959-963.
ABSTRACT | FULL TEXT  

Medical Management of Glaucoma
Alward
NEJM 1998;339:1298-1307.
FULL TEXT  

{beta}-Blocker-Induced Complications and the Patient With Glaucoma: Newer Treatments to Help Reduce Systemic Adverse Events
Stewart and Garrison
Arch Intern Med 1998;158:221-226.
FULL TEXT  

Questions Concerning the Role of Apraclonidine in the Management of Glaucoma
Robin
Arch Ophthalmol 1995;113:712-714.
ABSTRACT  

Open-Angle Glaucoma
Quigley
NEJM 1993;328:1097-1106.
FULL TEXT  

Topical Timolol and Serum Lipoproteins
Vogel
Arch Ophthalmol 1991;109:1341-1341.
ABSTRACT  

Topical Timolol and Serum Lipoproteins
Shaw and Weinreb
Arch Ophthalmol 1991;109:1341-1342.
ABSTRACT